Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanne van Wissen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Cardiovascular Risk|May 15, 2002
Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterolMarjel van Dam, Sanne van Wissen, John J P Kastelein
Current Opinion in Lipidology|March 14, 2002
Phenotypic variability in familial hypercholesterolaemia: an updateAngelique C M Jansen, Sanne van Wissen, Joep C Defesche, et al.
The American Journal of Cardiology|January 12, 2005
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemiaSanne van Wissen, Tineke J Smilde, Mieke D Trip, et al.
Atherosclerosis|November 6, 2002
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapySanne van Wissen, Mieke D Trip, Tineke J Smilde, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|December 13, 2003
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) studySanne van Wissen, Tineke J Smilde, Eric de Groot, et al.
Atherosclerosis|September 19, 2007
Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemiaMarijn C Meuwese, Mieke D Trip, Sanne van Wissen, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 30, 2004
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemiaLambertus J H van Tits, Tineke J Smilde, Sanne van Wissen, et al.
Atherosclerosis|April 6, 2004
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemiaGreetje J de Grooth, Tineke J Smilde, Sanne Van Wissen, et al.
Journal of the American College of Cardiology|January 22, 2003
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapyAnne G Semb, Sanne van Wissen, Thor Ueland, et al.
The Lancet. Haematology|October 14, 2018
Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysisElham E Amin, Arina J Ten Cate-Hoek, Annemieke C Bouman, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Cardiovascular Risk|May 15, 2002
Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterolMarjel van Dam, Sanne van Wissen, John J P Kastelein
Current Opinion in Lipidology|March 14, 2002
Phenotypic variability in familial hypercholesterolaemia: an updateAngelique C M Jansen, Sanne van Wissen, Joep C Defesche, et al.
The American Journal of Cardiology|January 12, 2005
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemiaSanne van Wissen, Tineke J Smilde, Mieke D Trip, et al.
Atherosclerosis|November 6, 2002
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapySanne van Wissen, Mieke D Trip, Tineke J Smilde, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|December 13, 2003
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) studySanne van Wissen, Tineke J Smilde, Eric de Groot, et al.
Atherosclerosis|September 19, 2007
Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemiaMarijn C Meuwese, Mieke D Trip, Sanne van Wissen, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 30, 2004
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemiaLambertus J H van Tits, Tineke J Smilde, Sanne van Wissen, et al.
Atherosclerosis|April 6, 2004
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemiaGreetje J de Grooth, Tineke J Smilde, Sanne Van Wissen, et al.
Journal of the American College of Cardiology|January 22, 2003
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapyAnne G Semb, Sanne van Wissen, Thor Ueland, et al.
The Lancet. Haematology|October 14, 2018
Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysisElham E Amin, Arina J Ten Cate-Hoek, Annemieke C Bouman, et al.
Pageof 2